Darmiyan is developing an AI-powered software platform that utilizes advanced medical image processing to detect and monitor Alzheimer's disease by analyzing cellular-level changes in brain MRI scans. This technology provides early identification of neurodegenerative conditions, enabling timely interventions and personalized treatment strategies.
Funding
$14.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACO+1Founders
Product
Problem
Early detection and monitoring of Alzheimer's disease and other neurodegenerative conditions are challenging due to the subtle nature of initial changes in brain tissue and the lack of widely accessible, non-invasive diagnostic tools. Current methods often fail to identify the disease until significant cognitive decline has already occurred, limiting the effectiveness of potential interventions.
Solution
Darmiyan's BrainSee software platform leverages advanced medical image processing and AI to analyze brain MRI scans at the cellular level, enabling early detection and monitoring of Alzheimer's disease. By quantifying changes in brain tissue architecture, BrainSee aims to identify neurodegenerative conditions at early stages, even before significant cognitive decline is evident. The technology provides clinicians with a tool to monitor patient-specific responses to interventions and facilitates the development of new drugs for Alzheimer's disease. BrainSee offers a non-invasive method for assessing brain health, with the goal of improving diagnostic and therapeutic outcomes for patients at risk of or affected by neurodegenerative diseases.
Target Audience
The primary target audience includes healthcare providers, such as neurologists and radiologists, pharmaceutical companies involved in Alzheimer's drug development, and clinical researchers focused on neurodegenerative diseases.
Features
- AI-powered analysis of standard clinical-grade MRI scans
- Quantifies cellular-level changes in brain tissue architecture
- Generates degeneration maps highlighting focal areas of degeneration
- Provides a five-year prognosis for patients presenting with amnestic mild cognitive impairment (MCI)
- Offers high test-retest reliability
- Aims for seamless integration into existing clinical workflows